Non-small Cell Lung Cancer Clinical Trials in Changsha, Hunan
72 recruitingChangsha, Hunan, China
Showing 1–20 of 72 trials
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer444 enrolled285 locationsNCT06452277
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled225 locationsNCT06345729
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled220 locationsNCT06170788
Recruiting
Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AbbVie698 enrolled317 locationsNCT04928846
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.626 enrolled770 locationsNCT04613596
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled383 locationsNCT05920356
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
Non-small Cell Lung CancerLung Cancer Associated With Cystic AirspacesMultiple Primary Lung Cancers
Central South University300 enrolled1 locationNCT06699979
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Phase 2
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Non-small Cell Lung CancerNasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.121 enrolled16 locationsNCT05956587
Recruiting
Phase 1Phase 2
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.104 enrolled21 locationsNCT05276726
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Colorectal, CancerNon-small Cell Lung CancerKRAS P.G12C+1 more
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital800 enrolled1 locationNCT04324164
Recruiting
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
Non-small Cell Lung Cancer
Shanghai Chest Hospital305 enrolled11 locationsNCT06443684
Recruiting
Phase 2
A Phase 2 Clinical Study of ABSK061 and ABSK043
Urothelial CarcinomaSolid TumorsNon-small Cell Lung Cancer+1 more
Abbisko Therapeutics Co, Ltd202 enrolled21 locationsNCT06632262
Recruiting
Phase 2
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital90 enrolled1 locationNCT05014464
Recruiting
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital70 enrolled1 locationNCT04324125
Recruiting
Phase 2
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital40 enrolled1 locationNCT05379803
Recruiting
Phase 2
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital120 enrolled1 locationNCT04322578